author: alexander colevas

Head and Neck Cancer, An Issue of Hematology/Oncology Clinics of North America,

Head and Neck Cancer, An Issue of Hematology/Oncology Clinics of North America,
Alexander Colevas
Medical
... EXAM trial: phase III, randomized, double blinded, placebo controlled Median PFS lenvatinib 18.3 mo vs placebo 3.6 mo; HR 5 0.21 (Schlumberger et al,47 2015) Vandetanib Progressive MTC ZETA trial: phase III, randomized, double blinded ...

© 2024 www.zuuk.org. All rights reserved.

This website uses cookies and collects data for optimal performance. Your continued use signifies agreement to our Privacy Policy.